Primer: US Payers and Biosimilar Formulary Placement
Q1, 2012
NOTE: This is ISR’s third installment of our "Biosimilars Primer" series tracking high-level views of US payers. Please also see Biosimilar Primers from US and European physicians and US pharmacists. Bundling options are available, please contact us at info@isrreports.com for more information.
Biosimilar, Follow-on Biologic (FoB), Follow-on protein product – whatever name you know them by you can’t surf the web, attend a conference, or read an industry publication without running into them.
To say the environment around Biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the Biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues.
This is a "Primer" and is not intended to cover the full range of issues currently at the heart of Biosimilar discussions. Rather, we believe this report serves as a very good starting point for sponsor/ innovator companies, generic manufacturers, and contract research organizations to begin to understand the thoughts and beliefs of US payers. We interviewed 30 high-level respondents from US-based Managed Care Organizations who are responsible for making formulary decisions.
From this report, readers will understand
- the familiarity US payers have with Biosimilars and their top-line concerns
- the current and future formulary decision-making structure around Biosimilars
- US Payers' view on reimbursement levels, including price expectations, reimbursement policy, and pharmacy-level substitutions
For more information on this report and to review the full table of contents, download our free report preview.
